DIVERSITY IN CLINICAL TRIALS House SponsorsRep. Marcus C. Evans, Jr.-Eva-Dina Delgado-Camille Y. Lilly-Kimberly Du Buclet, Yolonda Morris, Theresa Mah, Robert "Bob" Rita, Anne Stava-Murray, Kevin John Olickal, Cyril Nichols, Joyce Mason and Sharon Chung Senate Sponsors(Sen. Julie A. Morrison, Mary Edly-Allen-Mattie Hunter, Doris Turner and Adriane Johnson) 8/9/2024HousePublic Act . . . . . . . . . 103-0860 20 ILCS 2310/2310-730 new Amends the Department of Public Health Powers and Duties Law of the Civil Administrative Code of Illinois. Sets forth requirements for any State entity or hospital that receives funding from the National Institutes of Health to conduct clinical trials of drugs or medical devices. Provides that the Department of Public Health, in consultation with relevant research organizations, shall analyze and provide recommendations on: (i) the demographic groups and populations that are currently represented and underrepresented in clinical trials in the State, including representation of groups based on their geographic location; (ii) the barriers that prevent persons who are members of underrepresented demographic groups from participating in clinical trials in the State, including barriers related to transportation; and (iii) approaches for how clinical trials can successfully partner with others to provide outreach to underrepresented communities. Provides that the Department shall report to the General Assembly on the results of the study by July 1, 2025. Sets forth definitions of underrepresented community and underrepresented demographic group. Provides that the Department shall review guidance published by the United States Food and Drug Administration and use existing infrastructure to encourage participation in clinical trials of drugs and medical devices by persons who are members of underrepresented demographic groups. Authorizes the Department to apply for any grants related to the encouragement of underrepresented demographic groups related to the United Food and Drug Administration's guidance.House Floor Amendment No. 1 Requires the policy to include specific strategies for trial enrollment and retention of diverse participants, including, but not limited to, site location and access, sustained community engagement, and reducing burdens due to trial design or conduct, as appropriate (rather than a requirement for investigators who are conducting the clinical trials to collaborate with community-based organizations). Requires a policy to provide information to trial participants in languages other than English in accordance with current federal requirements. Requires the Department of Public Health to consult with the University of Illinois Cancer Center in making recommendations.Senate Committee Amendment No. 1 Replaces everything after the enacting clause with the provisions of the engrossed bill, and makes the following changes: Removes language requiring the Department of Public Health to adopt rules requiring State entities or hospitals to comply with specified requirements. Provides that the Department shall analyze and provide recommendations on specified information through voluntary reporting from research institutions and in consultation with community-based organizations and other stakeholders as appropriate and available (rather than in consultation with the Illinois Cancer Center, community-based organizations, and other research organizations). Provides that the Department shall issue its report and post the report on its website by July 1, 2026 (rather than reporting to the General Assembly by July 1, 2025). Provides that the Department shall establish an Internet website that provides information concerning methods for identifying and recruiting persons who are members of underrepresented demographic groups to participate in clinical trials and contains links to websites maintained by entities that are performing research relating to drugs or medical devices in the State (rather than establish a program to encourage participation in clinical trials of drugs and medical devices by persons who are members of demographic groups that are underrepresented in clinical trials). 2/9/2024HouseFiled with the Clerk by Rep. Marcus C. Evans, Jr. 2/9/2024HouseFirst Reading 2/9/2024HouseReferred to Rules Committee 3/5/2024HouseAssigned to Public Health Committee 4/4/2024HouseDo Pass / Short Debate Public Health Committee; 009-000-000 4/4/2024HouseAdded Co-Sponsor Rep. Yolonda Morris 4/4/2024HouseAdded Co-Sponsor Rep. Theresa Mah 4/4/2024HousePlaced on Calendar 2nd Reading - Short Debate 4/4/2024HouseHouse Floor Amendment No. 1 Filed with Clerk by Rep. Marcus C. Evans, Jr. 4/4/2024HouseHouse Floor Amendment No. 1 Referred to Rules Committee 4/10/2024HouseAdded Co-Sponsor Rep. Camille Y. Lilly 4/10/2024HouseRemoved Co-Sponsor Rep. Camille Y. Lilly 4/12/2024HouseAdded Chief Co-Sponsor Rep. Eva-Dina Delgado 4/15/2024HouseAdded Co-Sponsor Rep. Robert "Bob" Rita 4/15/2024HouseHouse Floor Amendment No. 1 Rules Refers to Public Health Committee 4/16/2024HouseHouse Floor Amendment No. 1 Recommends Be Adopted Public Health Committee; 007-000-000 4/17/2024HouseSecond Reading - Short Debate 4/17/2024HouseHeld on Calendar Order of Second Reading - Short Debate 4/19/2024HouseAdded Co-Sponsor Rep. Anne Stava-Murray 4/19/2024HouseAdded Co-Sponsor Rep. Kevin John Olickal 4/19/2024HouseHouse Floor Amendment No. 1 Adopted 4/19/2024HousePlaced on Calendar Order of 3rd Reading - Short Debate 4/19/2024HouseThird Reading - Short Debate - Passed 100-006-000 4/19/2024HouseAdded Co-Sponsor Rep. Cyril Nichols 4/24/2024SenateArrive in Senate 4/24/2024SenatePlaced on Calendar Order of First Reading 4/24/2024SenateChief Senate Sponsor Sen. Julie A. Morrison 4/24/2024SenateFirst Reading 4/24/2024SenateReferred to Assignments 4/30/2024SenateAssigned to Public Health 4/30/2024SenateRule 2-10 Committee Deadline Established As May 10, 2024 5/7/2024SenateSenate Committee Amendment No. 1 Filed with Secretary by Sen. Julie A. Morrison 5/7/2024SenateSenate Committee Amendment No. 1 Referred to Assignments 5/7/2024SenateSenate Committee Amendment No. 1 Assignments Refers to Public Health 5/7/2024SenateSenate Committee Amendment No. 1 Adopted 5/7/2024SenateAdded as Alternate Co-Sponsor Sen. Mary Edly-Allen 5/8/2024SenateDo Pass as Amended Public Health; 008-000-000 5/8/2024SenatePlaced on Calendar Order of 2nd Reading May 9, 2024 5/8/2024SenateAdded as Alternate Chief Co-Sponsor Sen. Mattie Hunter 5/9/2024SenateSecond Reading 5/9/2024SenatePlaced on Calendar Order of 3rd Reading 5/16/2024SenateThird Reading - Passed; 057-001-000 5/16/2024HouseArrived in House 5/16/2024HousePlaced on Calendar Order of Concurrence Senate Amendment(s) 1 5/20/2024HouseAdded Co-Sponsor Rep. La Shawn K. Ford 5/20/2024HouseRemoved Co-Sponsor Rep. La Shawn K. Ford 5/20/2024HouseSenate Committee Amendment No. 1 Motion Filed Concur Rep. Marcus C. Evans, Jr. 5/20/2024HouseSenate Committee Amendment No. 1 Motion to Concur Referred to Rules Committee 5/21/2024HouseSenate Committee Amendment No. 1 Motion to Concur Rules Referred to Public Health Committee 5/22/2024HouseSenate Committee Amendment No. 1 Motion to Concur Recommends Be Adopted Public Health Committee; 008-000-000 5/24/2024HouseAdded Chief Co-Sponsor Rep. Camille Y. Lilly 5/24/2024HouseAdded Chief Co-Sponsor Rep. Kimberly Du Buclet 5/25/2024HouseSenate Committee Amendment No. 1 House Concurs 105-000-000 5/25/2024HouseHouse Concurs 5/25/2024HousePassed Both Houses 5/25/2024HouseAdded Co-Sponsor Rep. Joyce Mason 5/25/2024HouseAdded Co-Sponsor Rep. Sharon Chung 5/26/2024SenateAdded as Alternate Co-Sponsor Sen. Doris Turner 5/26/2024SenateAdded as Alternate Co-Sponsor Sen. Adriane Johnson 6/21/2024HouseSent to the Governor 8/9/2024HouseGovernor Approved 8/9/2024HouseEffective Date January 1, 2025 8/9/2024HousePublic Act . . . . . . . . . 103-0860